Search

Your search keyword '"Sjoerd H. van der Burg"' showing total 442 results

Search Constraints

Start Over You searched for: Author "Sjoerd H. van der Burg" Remove constraint Author: "Sjoerd H. van der Burg"
442 results on '"Sjoerd H. van der Burg"'

Search Results

1. T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors

2. Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment

3. The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent

4. Characterization of the early cellular immune response induced by HPV vaccines

5. Tumor-Infiltrating T Cells Can Be Expanded Successfully from Primary Uveal Melanoma after Separation from Their Tumor Environment

7. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4

8. Monalizumab: inhibiting the novel immune checkpoint NKG2A

9. High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status

10. Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling

11. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy

12. Demarcated thresholds of tumor-specific CD8 T cells elicited by MCMV-based vaccine vectors provide robust correlates of protection

13. Photochemical Internalization Enhanced Vaccination Is Safe, and Gives Promising Cellular Immune Responses to an HPV Peptide-Based Vaccine in a Phase I Clinical Study in Healthy Volunteers

14. The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma

15. TEIPP peptides: exploration of unTAPped cancer antigens

16. T cells specific for a TAP-independent self-peptide remain naïve in tumor-bearing mice and are fully exploitable for therapy

17. Features of Effective T Cell-Inducing Vaccines against Chronic Viral Infections

18. T Cells Engaging the Conserved MHC Class Ib Molecule Qa-1b with TAP-Independent Peptides Are Semi-Invariant Lymphocytes

19. Managing Multi-center Flow Cytometry Data for Immune Monitoring

20. High-Risk Human Papillomavirus Targets Crossroads in Immune Signaling

21. The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy

22. Managing Multi-center Flow Cytometry Data for Immune Monitoring

23. Monitoring of the Immune Dysfunction in Cancer Patients

25. Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial

26. PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance

27. Data from CD39 Identifies the CD4+ Tumor-Specific T-cell Population in Human Cancer

28. Table TS2 from Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy

29. Figure S2 from Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy

30. Supplementary Movie S2 from Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells

31. Data from Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells

32. Data from Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy

34. Supplementary Methods SM1 from Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy

36. Supplementary Figure legends from Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature

37. Supplemental Figure S3 from Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression

40. Supplementary Figures 1 through 5 and supplementary Tables 1 through 3 from Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature

41. Data from Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature

42. Data from Digital PCR-Based T-cell Quantification–Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma

44. Data from Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression

45. Data from CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy

46. Supplemental figure 3 from Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death

48. Supplemental Video 2 from Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death

49. Supplemental figure 2 from Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death

50. Supplemental figure 1 from Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death

Catalog

Books, media, physical & digital resources